Merck & Co Inc（MRK）の財務MRKMerck & Co Inc

Merck & Co Inc (MRK) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Oncology-Keytruda, accounting for 48.5% of total sales, equivalent to $7.91B. Other significant revenue streams include Vaccines -Gardasil/Gardasil and Animal Health-Livestock. Understanding this composition is critical for investors evaluating how MRK navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Merck & Co Inc maintains a gross margin of 74.64%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1.51%, while the net margin is -8.05%. These profitability ratios, combined with a Return on Equity (ROE) of 6.98%, provide a clear picture of how effectively MRK converts its operational activities into shareholder value.

In the context of the broader market, MRK competes directly with industry leaders such as ONC and ABBV. With a market capitalization of $363.59B, it holds a significant position in the sector. When comparing efficiency, MRK's gross margin of 74.64% stands against ONC's 89.76% and ABBV's 74.74%. Such benchmarking helps identify whether Merck & Co Inc is trading at a premium or discount relative to its financial performance.

Merck has demonstrated strong revenue growth with total revenue reaching $17.28 billion in Q3 2025, and a gross margin of 78.10% in the same quarter, indicating efficient cost management. However, net income has turned negative in recent quarters, with a net income of -1.34 billion in Q2 2026, which raises concerns about profitability.